Lymphadenectomy for gastric adenocarcinoma: Should west meet east?

Oncologist

Volumn 14, Issue 9, 2009, Pages 871-882

  Yoon, Sam S ^a   Yang, Han Kwang ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Seoul National University Hospital   (South Korea)

Author keywords

Gastric cancer; Lymphadenectomy; Outcomes; Review; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; JAPAN; KOREA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAL EXPERT; MORBIDITY; NETHERLANDS; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; UNITED KINGDOM;

ADENOCARCINOMA; EUROPE; GASTRECTOMY; HUMANS; JAPAN; KOREA; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 70349427092     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0070     Document Type: Review

References (68)

1. World Health Organization Cancer. World Health Organization Fact Sheet No. 297. February 2009. Available at http://www.who.int/mediacentre/ factsheets/fs297/en/index.html, accessed September 1, 2009.
2. Lee J, Demissie K, Lu SE et al. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007;14:78-85. (Pubitemid 46172395)
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Gotoda T, Yanagisawa A, SasakoMet al. Incidence of lymph node metastasis from early gastric cancer: Estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219-225.
5. Jansen EP, Boot H, VerheijMet al. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005;23:4509-4517. (Pubitemid 46196580)
6. Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-999. (Pubitemid 26112171)
7. Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
8. Uyama I, Ogiwara H, Takahara T et al. Spleen- and pancreas-preserving total gastrectomy with superextended lymphadenectomy including dissection of the para-aortic lymph nodes for gastric cancer. J Surg Oncol 1996; 63:268-270. (Pubitemid 27009245)
9. Biffi R, Chiappa A, Luca F et al. Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: Low morbidity and mortality rates in a single center series of 250 patients. J Surg Oncol 2006;93:394-400.
10. Degiuli M, Sasako M, Ponti A et al. Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1998;16:1490-1493. (Pubitemid 28175770)
11. Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303-308. (Pubitemid 38425649)
12. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol 2006;7:309-315.
13. Hundahl SA, Macdonald JS, Benedetti J et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Ann Surg Oncol 2002;9:278-286. (Pubitemid 34298633)
14. Peeters KC, Hundahl SA, Kranenbarg EK et al. Low Maruyama index surgery for gastric cancer: Blinded reanalysis of the Dutch D1-D2 trial. World J Surg 2005;29:1576-1584.
15. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery. Jpn J Surg 1973;3:61-71.
16. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma- 2nd English edition. Gastric Cancer 1998;1:10-24.
17. Park DJ, Lee HJ, Kim HH et al. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005;92:1099-1102.
18. Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-2773. (Pubitemid 41079893)
19. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137. (Pubitemid 34984604)
20. Smith DL, Elting LS, Learn PA et al. Factors influencing the volumeoutcome relationship in gastrectomies: A population-based study. Ann Surg Oncol 2007;14:1846-1852.
21. Wanebo HJ, Kennedy BJ, Chmiel J et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583-592.
22. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. (Pubitemid 34936653)
23. American Joint Committee on Cancer. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer, 2002:1-99.
24. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg 2007;94: 263-264. (Pubitemid 46423841)
25. Smith JK, McPhee JT, Hill JS et al. National outcomes after gastric resection for neoplasm. Arch Surg 2007;142:387-393.
26. Marcus SG, Cohen D, Lin K et al. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg 2003;7:1015-1022; discussion 1023. (Pubitemid 37524069)
27. Lee JH, Ryu KW, Lee JH et al. Learning curve for total gastrectomy with D2 lymph node dissection: Cumulative sum analysis for qualified surgery. Ann Surg Oncol 2006;13:1175-1181.
28. Stomach. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer, 2002:99-106.
29. Reid-Lombardo KM, Gay G, Patel-Parekh L et al. Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from the National Cancer Data Base. J Gastrointest Surg 2007;11:410- 419; discussion 419-420.
30. Coburn NG, Swallow CJ, Kiss A et al. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006;107:2143-2151. (Pubitemid 44665647)
31. Mullaney PJ, Wadley MS, Hyde C et al. Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer. Br J Surg 2002;89:1405-1408.
32. Bouvier AM, Haas O, Piard F et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002;94:2862-2866. (Pubitemid 34547684)
33. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: Data from a large US-population database. J Clin Oncol 2005;23:7114-7124. (Pubitemid 46260299)
34. Estes NC, Macdonald JS, Touijer K et al. Inadequate documentation and resection for gastric cancer in the United States: A preliminary report. Am Surg 1998;64:680-685. (Pubitemid 28294697)
35. Shen JY, Kim S, Cheong JH et al. The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancer. Cancer 2007; 110:745-751. (Pubitemid 47257649)
36. Kim JP, Lee JH, Kim SJ et al. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998; 1:125-133.
37. Siewert JR, Böttcher K, Stein HJ et al. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-461. (Pubitemid 30194389)
38. Marchet A, Mocellin S, Ambrosi A et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: Results from an Italian multicentric study in 1853 patients. Ann Surg 2007;245: 543-552.
39. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
40. D'Angelica M, Gonen M, BrennanMFet al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-816.
41. Yoo CH, Noh SH, Shin DW et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-242. (Pubitemid 30088655)
42. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357: 1810-1820. (Pubitemid 350044801)
43. Lee HK, Yang HK, Kim WH et al. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 2001;88:1408-1412. (Pubitemid 32955426)
44. Siewert JR, Böttcher K, Roder JD et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 1993;80:1015-1018.
45. Yildirim E, Celen O, Berberoglu U. The Turkish experience with curative gastrectomies for gastric carcinoma: Is D2 dissection worthwhile? J Am Coll Surg 2001;192:25-37.
46. Karpeh MS, Leon L, Klimstra D et al. Lymph node staging in gastric cancer: Is location more important than number? An analysis of 1,038 patients. Ann Surg 2000;232:362-371. (Pubitemid 30677824)
47. Maruyama K, Sasako M, Kinoshita T et al. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995;19:532-536.
48. Roggin KK, Posner MC. D3 or not D3. . . that is not the question. Lancet Oncol 2006;7:279-280.
49. Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: A review. Gastric Cancer 2005;8:78-85. (Pubitemid 40655516)
50. Kim S, Lim DH, Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-1285. (Pubitemid 41628018)
51. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
52. Sasako M, Sano T, Katai H et al. Radical surgery. In: Sugimura T, Sasako M. Gastric Cancer. Oxford: Oxford University Press, 1997:223-249.
53. Kitamura K, Nishida S, Ichikawa D et al. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Br J Surg 1999;86:119-122. (Pubitemid 29051921)
54. Kodera Y, Yamamura Y, Shimizu Y et al. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World J Surg 1997;21:622- 627; discussion 627-628. (Pubitemid 27268559)
55. Sasako M, McCulloch P, Kinoshita T et al. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-351.
56. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077. (Pubitemid 41095139)
57. Csendes A, Burdiles P, Rojas J et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401-407. (Pubitemid 34289730)
58. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563.
59. Sano T, Yamamoto S, Sasako M. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan Clinical Oncology Group study JCOG 0110-MF. Jpn J Clin Oncol 2002; 32:363-364. (Pubitemid 43102790)
60. Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359: 453-462.
61. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-425. (Pubitemid 17137100)
62. Kampschöer GH, Maruyama K, van de Velde CJ et al. Computer analysis in making preoperative decisions: A rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989;76:905-908. (Pubitemid 19233272)
63. Siewert JR, Kelsen D, Hoelscher AH. Gastric Cancer Diagnosis and Treatment- An Interactive Training Program. Berlin: Springer Electronic Media, 2000.
64. Bollschweiler E, Boettcher K, Hoelscher AH et al. Preoperative assessment of lymph node metastases in patients with gastric cancer: Evaluation of the Maruyama computer program. Br J Surg 1992;79:156-160.
65. Guadagni S, de Manzoni G, Catarci M et al. Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg 2000;24:1550-1558. (Pubitemid 32047286)
66. Hundahl SA, Peeters KC, Kranenbarg EK et al. Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer: Autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer 2007;10:84-86.
67. Karpeh MS Jr. Should gastric cancer surgery be performed in community hospitals? Semin Oncol 2005;32(suppl 9):S94-S96.
68. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma- 2nd English edition-response assessment of chemotherapy and radiotherapy for gastric carcinoma: Clinical criteria. Gastric Cancer 2001; 4:1-8.